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Background: Cardiotoxicity is a serious side effect to treatment with 5-fluorouracil (5-FU), but the underlying
mechanisms are not fully understood. The objective of this systematic review was to evaluate the pathophysiology of
5-FU- induced cardiotoxicity.
Methods: We systematically searched PubMed for articles in English using the search terms: 5-FU OR 5-fluorouracil
OR capecitabine AND cardiotoxicity. Papers evaluating the pathophysiology of this cardiotoxicity were included.
Results: We identified 27 articles of 26 studies concerning the pathophysiology of 5-FU-induced cardiotoxicity. The
studies demonstrated 5-FU-induced: hemorrhagic infarction, interstitial fibrosis and inflammatory reaction in the
myocardium; damage of the arterial endothelium followed by platelet aggregation; increased myocardial energy
metabolism and depletion of high energy phosphate compounds; increased superoxide anion levels and a reduced
antioxidant capacity; vasoconstriction of arteries; changes in red blood cell (RBC) structure, function and metabolism;
alterations in plasma levels of substances involved in coagulation and fibrinolysis and increased endothelin-1 levels
and N-terminal-pro brain natriuretic peptide levels. Based on these findings the proposed mechanisms are: endothelial
injury followed by thrombosis, increased metabolism leading to energy depletion and ischemia, oxidative stress causing
cellular damage, coronary artery spasm leading to myocardial ischemia and diminished ability of RBCs to transfer oxygen
resulting in myocardial ischemia.
Conclusions: There is no evidence for a single mechanism responsible for 5-FU-induced cardiotoxicity, and the
underlying mechanisms might be multifactorial. Further research is needed to elucidate the pathogenesis of this
side effect.
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5-Fluorouracil (5-FU) and capecitabine are chemothera-
peutics used to treat solid cancers, including gastrointes-
tinal cancers, breast cancer, head and neck cancer and
pancreatic cancer. Capecitabine is a 5-FU pro-drug, that
is converted to 5-FU inside tumour cells [1]. A severe
side effect to 5-FU and capecitabine-based treatment is
cardiotoxicity, which often presents as myocardial ische-
mia, but to a lesser extent cardiac arrhythmias, hyper-
and hypotension, left ventricular dysfunction, cardiac
arrest and sudden death [2-7]. The incidence of 5-FU-
induced cardiotoxicity varies between 0-35% and may* Correspondence: anne.polk@hotmail.com
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unless otherwise stated.depend on dose, cardiac comorbidity and schedule of
chemotherapy [2,3,5].
The clinical handling of 5-FU-induced cardiotoxicity is
difficult as the pathophysiological mechanisms under-
lying this cardiotoxicity remain undefined [2,8-13]. Several
mechanisms have been proposed, including vascular endo-
thelial damage followed by coagulation, ischemia secondary
to coronary artery spasm, direct toxicity on the myocar-
dium and thrombogenicity due to altered rheological fac-
tors. The present review addresses the pathophysiology of
5-FU- and capecitabine-induced cardiotoxicity and dis-
cusses the evidence for the proposed mechanisms.Method
This systematic review is conducted according to the
PRISMA guidelines [14] (Additional file 1).. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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We searched PubMed (1966–2013) for publications in
English using the search string: (5-FU or 5-fluorouracil
or capecitabine) AND cardiotoxicity. The last search was
carried out in October 2013. Additionally we hand-
searched reference lists of retrieved papers.
Study selection process
All citations retrieved were reviewed on full citation,
abstracts and indexing terms (where provided in the
databases) by two authors independently. They were
rated as “relevant”, “possibly relevant” or “not relevant”.
Full-text publications of all potentially relevant articles
were reviewed for eligibility independently by the same
two authors. All disagreements in rating or eligibility
were resolved by discussion of the full-text articles till
consensus was reached. All articles or abstracts in English
exploring the pathophysiology of 5-FU or capecitabine car-
diotoxicity were eligible. Case reports were excluded. Full
articles were obtained, and references were checked for
additional relevant articles.
Data extraction
The studies were grouped into in vitro studies (studies
on cultured cells or cell lines), ex vivo animal studies
(conducted on functional organs that had been removed
from the intact organism), in vivo animal studies
(conducted on living organisms in their normal intact
state) and human studies. One author extracted the follow-
ing data from all studies where provided: the type of study
(in vitro, ex vivo animal, in vivo animal or human), the ex-
perimental model used, the number of tests objects, the
parameters evaluated, the methods applied and the results
of the performed tests.
Results
Twenty-seven papers of 26 studies were included (eight
in vitro studies, two ex vivo animal studies, nine in vivo
animal studies, six human studies and one study with
results from both in vitro and human experiments)
(Figure 1). All studies evaluated the pathophysiology
of 5-FU-induced cardiotoxicity. We did not identify any
studies evaluating the pathophysiology of capecitabine-
induced cardiotoxicity. Additional file 2 shows a table
with characteristics and results of the included studies.
The positive, negative and conflicting findings from these
studies are summarized in Table 1.
Histopathological studies of the myocardium
The histopathological effects of 5-FU- were examined in
two animal studies [15]. In rat hearts, multifocal intersti-
tial hemorrhages, multifocal myofiber necrosis, inflam-
matory reactions including perivascular involvement,
pericarditis, valvulitis and vascular changes, were found[15]. The vascular changes included dilated vessels, rup-
tured vascular walls, extravasation of blood and micro-
thrombosis. In rabbits, a single high intravenous dose
resulted in hemorrhagic infarction of the ventricle walls,
proximal spasms of the coronary arteries and lethal out-
come for all rabbits within 1 day [16]. In contrast, repeated
lower doses resulted in left ventricular hypertrophy due to
reticular interstitial fibrosis with edema, concentric fibrous
thickening of the intima of small distal coronary arteries
and disseminated foci of necrotic myocardial cells [16].
Whether the differences in histopathological effects were
species specific, or due to different doses, is not clear.
Histopathological studies of the arteries
Four studies [9,22-24] examined the histopathological ef-
fects of 5-FU on the arterial endothelium in rabbits.
Scanning electron microscopy of the arteries showed ex-
tensive cytolysis, denudation of the underlying internal
elastic lamina, platelet aggregation and fibrin formation
[9,22-24]. Areas of contracted vessel walls with contracted
endothelial cells were present [9,22-24]. Cell detachment
was frequently seen and endothelial cells presented with a
range of morphologic features compatible with cytolysis
[9,22-24]. The endothelial damage was comparable in ar-
teries exposed to direct injection of 5-FU and arteries ex-
posed to 5-FU through systemic circulation [24]. The
endothelial changes were most pronounced on day 3 after
5-FU injections and had diminished on day 7 and day 14
[9]. Concomitant treatment with probucol, a lipid-lowering
drug with strong antioxidant properties, abrogated the ef-
fects of 5-FU on the endothelium [24], while concomitant
treatment with dalteparin, a low-molecular-weight heparin,
resulted in a somewhat different picture with endothelial
damage on day 3, diminishing on day 7 but increasing
again by day 14 [9]. Dalteparin prevented fibrin formation
and to a lesser extent platelet aggregation [9].
Studies on cultured myocardial and endothelial cells
In vitro treatment of H9c2 rat cardiomyocytes with
5-FU induced a time- and dose-dependent growth in-
hibition that was enhanced by levofolene [17]. Apoptosis
was more frequent in 5-FU- and levofolene-treated H9c2
cells compared with colon cancer cells, and cleavage of cas-
pase 3, an effector caspase in the apoptotic pathways, was
increased in 5-FU treated H9c2 cells [17]. Moreover, super-
oxide anion levels increased [17]. Comparing the toxicity
of 5-FU on cardiomyocytes and endothelial cells from rat
hearts, Wenzel and Cosma [36] found that 5-FU induced
more severe metabolic and morphological changes in
endothelial cells than in cardiomyocytes. In contrast, an
in vitro study of human endothelial cells and bovine endo-
thelial cells showed no effect on cell death of 5-FU, but
decreased (3H)thymidine incorporation, decreased total
cellular protein levels and increased prostacyclin release
Figure 1 Study identification and selection process.
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ings suggest differences in susceptibility between dif-
ferent cell lines to the direct toxic effects from 5-FU
[17,36] and possibly even different cellular responses
to the same stressor [17]. The toxic effects may not be
lethal for the cells, but may reflect reversible interfer-
ence with cellular function [36].
Studies of myocardial metabolism and hemodynamic
function
Studies of myocardial metabolism in guinea pigs showed
that 5-FU induced a decrease in myocardial high en-
ergy phosphate levels [12,36,37] and accumulation of
citrate in the myocardium [12] reflecting increased
anaerobic metabolism. These changes were associated
with electrocardiographic (ECG) changes suggestive of
myocardial ischemia occurring around 3 hours after
intravenous administration of 5-FU [12]. The deple-
tion of high energy compounds was not associated
with alterations in myocardial blood flow [12] as myo-
cardial blood flow remained unchanged during 5-FU
treatment. In contrast, Millart et al. [20] found that
mean coronary flow was consistently increased in 5-FU-
pre-treated rat hearts. This discrepancy can be due
to different species, different experimental models or
different methods to measure coronary flow. Like-
wise, Tamatsu et al. [37] showed that the experimental
model used (open-chest or closed-chest) influenced
the magnitude of depletion in high energy phosphate
compounds [37].
Millart et al. [20] found no changes in oxygen uptake
and cardiac contractility during perfusion of the isolated
perfused rat heart with 1 mg/L 5-FU for 80 minutes.However, when rats where pre-treated with 5-FU (50 mg/kg
intraperitoneally for 5 days) before killing and excision
of the hearts, oxygen consumption and mean coronary
flow were significantly higher compared with controls
[20]. Also, a negative inotropic effect was seen in 5-FU
pre-treated rats. In contrast, Satoh et al. [21] reported
that 5-FU had a positive inotropic effect on the atria,
and a positive chronotropic effect on the sinoatrial
node, in an isolated sinoatrial node and atrial model.
These conflicting findings may be due to the different ani-
mal models used.
Studies of the myocardial antioxidant system
The influence of 5-FU treatment on the antioxidant sys-
tem in myocardial tissue was studied by Durak et al. [18].
They found lowered activities of superoxide dismutase
and glutathione peroxidase accompanied by higher cata-
lase activity in 5-FU-treated female guinea pigs. The anti-
oxidant potential, defined relative to malondialdehyde
(MDA) levels, declined in 5-FU-treated animals com-
pared with controls, while MDA levels increased [18]. A
slight increase in intratissular MDA levels (not signifi-
cant) and lower α-hydroxybutyrate dehydrogenase activ-
ity were demonstrated by Millart et al. [19].
The iron level was 20% higher in 5-FU-treated rat
myocardial tissue compared with controls in one study
[19], while another study of open-chest guinea pigs
could not demonstrate increased iron levels in the myo-
cardium after 5-FU infusion [18]. The two studies used
comparable methods for iron content determination
(flame atomic absorption spectrophotometry and atomic
absorption spectroscopy), but they used different species
and dosages. Magnesium, potassium, calcium and copper
Table 1 Positive, negative and conflicting findings from the included studies
Myocardium and hemodynamic function
Positive Hemorrhagic infarction, interstitial fibrosis and inflammatory reaction in the myocardium [15,16]
Induction of apoptosis and increased oxidative stress [17]
Impaired antioxidant defense system and lipid peroxidation [18,19]
Depletion of high energy phosphate compounds and accumulation of citrate in the myocardium [12]
Increased oxygen consumption [20]
Positive chronotropic effect on the sinus node [21]
Conflicting or unclarified Increased/no change in iron levels in the myocardium [18,19]
Positive/negative inotropic effect on the heart [20,21]
Increased/no change in myocardial blood flow [12,20]
Negative No changes in magnesium, potassium, calcium or copper levels in the myocardium [18,19]
No changes in blood pressure and heart rate [12]
Arteries
Positive Endothelial damage followed by platelet aggregation [9,22-24]
Decreased DNA synthesis, decreased total cellular protein levels and increased prostacyclin release from
endothelial cells [25]
Vasoconstriction of arteries [26-28]
Rheological factors and RBCs
Positive Changes in erythrocyte structure, function and metabolism [29-32]
Negative Decreased and not increased blood and plasma viscosity [33]
Substances in blood samples
Positive Rise in fibrinopeptide A activation and reduction in protein C activity compared with protein C antigen [10]
Decrease in fibrinogen levels [33]
Decrease in coagulation factors II + VII + X and increase in lactic acid, NT-proBNP, von Willebrand factor and
fibrin D-dimer levels and urine albumin-to-creatinine-ratio [8,34]
Increased plasma levels of endothelin-1 [35]
Conflicting or unclarified A trend towards increased levels of big endothelin [28]
Negative No change in angiotensin II levels [27]
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ment in both studies [18,19].
Studies of vasoconstriction of arteries
5-FU-induced vasoconstriction has been demonstrated
in three studies [26-28]. Two studies [27,28] showed that
vasoconstriction of the brachial artery occurred in patients
immediately after 5-FU infusion. The 5-FU-induced vaso-
constriction was short-lived, reoccurred with repeated
5-FU injections and was abolished by glycerol nitrate
[28]. In the study by Südhoff et al. [28] no patients had
symptoms of cardiotoxicity, and in the study by Salepci
et al. [27] three of 31 patients treated with 5-FU developed
chest pain. ECG abnormalities were documented in five of
31 patients by Salepci et al. [27], while ECG recordings
were not performed by Südhoff et al. [28].
Mosseri et al. [26] studied 5-FU-induced vasoconstric-
tion in vitro using isolated aorta rings excised from rab-
bits. The prevalence of vasoconstriction correlated withthe molar concentration of 5-FU and the magnitude was
proportional to the concentration of 5-FU. The magni-
tude of vasoconstriction was similar for aorta rings, with
functionally preserved endothelium and aorta rings with
purposely disrupted endothelium indicating that an intact
endothelium was not a prerequisite for 5-FU-induced
vasoconstriction [26]. 5-FU-induced vasoconstriction was
abolished by nitroglycerin, and acetylcholine-induced
endothelium-dependent relaxation was unaffected by
5-FU-treatment [26], suggesting that 5-FU-induced vaso-
constriction is not due to impairment of endothelial re-
laxation pathways. Pre-treatment with staurosporine, a
protein kinase C (PK-C) inhibitor, reduced 5-FU-induced
vasoconstriction, while pre-treatment with phorbol-12,13-
dibutyrate, an activator of PK-C, increased the magnitude
of 5-FU-induced vasoconstriction 23-fold [26]. In contrast,
neomycin, an inhibitor of phosphoinositide turnover, and
the cyclo-oxygenase inhibitor, indomethacin, did not alter
the magnitude of 5-FU-induced vasoconstriction [26]. All
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[26], including the α-adrenergic receptor blocker phentola-
mine, the β-adrenergic receptor blocker propranolol, the
H1 receptor inhibitor diphenhydramine, the H2 receptor
inhibitor cimetidine and the Ca2+ channel blockers verap-
amil and diltiazem failed to alter the magnitude of 5-FU-
induced vasoconstriction [26].
Studies on blood rheology and red blood cells
In vitro studies of red blood cells (RBCs) incubated
in 5-FU showed a dose-dependent, reversible trans-
formation of RBCs into echinocytic shape [29,30], which
resulted in impaired transit through small pores [29].
Also, alterations in membrane fluidity and RBC metabol-
ism were observed [30-32]: potassium efflux increased
[30], oxygen tension (pO2) decreased [31,32], deoxy-
hemoglobin levels increased [32], intracellular ATP levels
declined and the intracellular 2,3-bisphosphoglycerate (2,3-
BPG) concentration rose [31,32]. Spasojevic et al. [32] mea-
sured 31P-nuclear magnetic resonance (31P-NMR) spectra
of blood samples obtained from five patients treated
with 5-FU and cisplatin, and found a downfield shift in
31P-NMR spectra in vivo. However, the number of patients
was too small for statistical analysis.
Baerlocher et al. [29] demonstrated a continuous de-
crease in blood viscosity with increasing 5-FU concen-
trations at low shear rates (the rate of change of velocity
at which one layer of fluid passes over an adjacent layer)
and increasing blood viscosity at high shear rates. 5-FU
had no effect on plasma viscosity in this in vitro study
[29]. In contrast, plasma viscosity and blood viscosity at
both natural and standardized hematocrit decreased in
blood samples from 11 patients receiving 5-FU and cis-
platin [33]. These inconsistent findings may have re-
sulted from differences in exposure to 5-FU between
in vitro and human studies.
Studies of substances in blood samples from humans
Studies of the clotting-fibrinolytic system have shown in-
creased levels of D-dimer [8] and fibrinopeptide A [10],
decreased levels of fibrinogen [33] and coagulation fac-
tors II + VII + X [8], and decreased activity of the coagu-
lation inhibitor, protein C, in blood [10]. Additionally,
von Willebrand factor, which mediates the adherence
and aggregation of platelets to the subendothelium, in-
creased during 5-FU therapy [8]. However, none of the
abnormalities reported in these studies was confined to
patients experiencing cardiotoxicity [8,10,33]. Jensen
et al. [8,34] reported that coagulation factors II + VII + X
decreased during infusion, while levels of lactic acid,
plasma N-terminal pro brain natriuretic peptide (NT-
proBNP), von Willebrand factor, fibrin D-dimer, and
the urine albumin-to-creatinine-ratio, increased. These
changes were transient and only NT-proBNP levels werehigher in patients experiencing cardiotoxicity [34]. A
trend towards increased levels of big endothelin, a pre-
cursor to endothelin-1, was demonstrated in one study,
but a large inter-individual variation was found [28]. Thyss
et al. [35] reported higher plasma levels of endothelin-1
in 5-FU-treated patients compared with cancer patients
receiving non-5-FU-based chemotherapy. Also, patients
experiencing cardiotoxicity during 5-FU treatment had
higher endothelin-1 levels compared with patients without
cardiotoxicity [35]. Angiotensin II levels remained un-
changed during 5-FU treatment [27]. Thus, several sub-
stances in blood were affected by 5-FU treatment, but
only NT-proBNP and endothelin-1 were associated with
cardiotoxicity.
Discussion
The experimental studies and human studies included in
this review showed that 5-FU induced a range of effects
on the heart, on the vascular endothelium and at the
cellular level of RBCs, myocardial and endothelial cells.
However, to what extent these effects are involved in the
pathogenesis of the clinical cardiotoxicity is more diffi-
cult to resolve. In the following, we discuss the findings
and their possible role in the pathogenesis of 5-FU-
induced clinical cardiotoxicity.
Histopathological changes
Animal studies showed that 5-FU induced pathological
changes in the myocardium as well as on the endothe-
lium, in arterial vessel walls. Although the endothelial
studies did not involve the coronary arteries, there was
evidence of systemic endothelial injury [24]. In the myo-
cardium, the damages seemed to depend on the dose of
5-FU administered, as high doses led to more pronounced
injuries [16].
It is not clear to what extent the histopathological fea-
tures demonstrated in animal studies can be found in
patients experiencing clinical signs of cardiotoxicity, as
no biopsy studies have been performed in patients
experiencing cardiotoxicity. Human myocardial biopsy
samples are hard to obtain, and it is doubtful whether
they will provide new and meaningful information as
most cancer patients are exposed to several drugs.
Therefore, the use of experimental models is necessary
to obtain better insight into the mechanisms of 5-FU-
cardiotoxicity. One approach is to use cellular models of
isolated cardiac myocytes, which have been extensively
used to study the cardiotoxic effects of anthracyclines
[38-46]. Likewise, Lamberti et al. [17] used rat H9c2 car-
diomyocytes to demonstrate that 5-FU toxicity in cardio-
myocytes was largely due to induction of apoptosis, as
opposed to cytotoxicity in colon cancer cells, which was
more likely due to necrosis or autophagy. Whether this
finding reflects a different mechanism of cardiotoxicity
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merely different cellular responses to the same stressor, is
not clear.
5-FU induced endothelial injury and thrombus formation
Platelet aggregation and fibrin formation on sites of
endothelial injury in scanning electron microscopy stud-
ies of rabbit vascular endothelium suggested that the
pathophysiological mechanism of 5-FU-induced cardio-
toxicity involved a thrombogenic effect of 5-FU, second-
ary to endothelial injury [9,22-24]. However, the absence
of vascular occlusions in many patients undergoing cor-
onary angiography for 5-FU-induced chest pain does not
support thrombosis as a main mechanism [47-63]. On
the other hand, a state of ongoing intravascular coagula-
tion was evident from studies of the clotting-fibrinolytic
system. A pro-coagulant state is common in cancer pa-
tients and is triggered by tumor-produced pro-coagulant
factors and tumor-cell-derived cytokines [64]. Several
studies have shown that fibrin and fibrinogen degrad-
ation products are elevated in patients with colorectal
cancer [65-68]. Also, von Willebrand factor is increased
in cancer patients and has been correlated to advanced
tumor state [69-72]. In the study by Jensen et al. [8] 47
of 106 patients had baseline plasma levels of von Willeb-
rand factor above the reference interval before 5-FU
therapy, but 97 of 106 patients had von Willebrand fac-
tor levels above the reference interval during 5-FU ther-
apy. Hence, it is likely that both the underlying cancer
disease and exposure to 5-FU contribute to the observed
alterations in plasma levels of substances involved in co-
agulation and fibrinolysis. However, it is unlikely that
these alterations play an important role in the pathogen-
esis of 5-FU-induced cardiotoxicity, as they were not
confined to patients experiencing cardiotoxicity.
The role of myocardial metabolism in 5-FU induced
cardiotoxicity
Animal studies of myocardial metabolism demonstrated
depletion of high energy phosphate compounds, citrate
accumulation and increased oxygen consumption in the
heart after pre-treatment with 5-FU [12,20,37]. Deple-
tion in high energy phosphate compounds can result
from increased oxygen consumption leading to insuffi-
cient oxygen supply, increased anaerobic metabolism,
or to metabolic derangements produced by 5-FU. The
stable and increased myocardial blood flow observed in
two studies suggests that insufficient blood and oxygen
supply is not a contributing factor. Instead, Suzuki et al.
[73] reported that the respiratory control rate of myo-
cardial mitochondria was significantly lower in rabbits
treated with 5-FU compared with controls. Therefore,
Millart et al. [20] proposed that the increase in anaer-
obic metabolism and the increase in oxygen uptakecould be due to reduced aerobic efficiency resulting from
mitochondrial uncoupling. Uncoupling of the mitochon-
drial respiratory chain results in increased basal oxygen
consumption and decreased ATP-production. This theory
should be further studied.
The theory of oxidative stress
The pathogenesis of 5-FU induced cardiotoxicity may
involve oxidative stress, as increased levels of super-
oxide anion were demonstrated in H9c2 cells after 5-FU
treatment [17]. Reactive oxygen species (ROS), like super-
oxide anions, are under normal physiological conditions
cleared by antioxidant defense systems, such as so-
dium oxide dismutase (SOD) and glutathione peroxidase
(GSH-Px). Superoxide anion is dismutated to hydrogen
peroxide (H2O2) in a process catalyzed by SOD, and H2O2
is then eliminated by catalase or GSH-Px [74]. The activ-
ities of SOD and GSH-Px were lowered in 5-FU treated
guinea pigs [18] demonstrating a reduced antioxidant cap-
acity. If not eliminated by cellular antioxidant systems,
superoxide anions can generate the highly reactive and
toxic hydroxyl radicals (−OH) through the Haber–Weiss
reaction, which is catalyzed by iron [74,75]. Increased ROS
levels inside cells lead to oxidation of macromolecules,
including lipids, nucleic acids, and proteins, thereby dis-
turbing cellular functions [75]. MDA is a frequently used
marker of lipid peroxidation [76], and MDA levels were el-
evated in guinea pig hearts after 5-FU-treatment [18], and
slightly elevated (but not significantly) in isolated rat
hearts after 5-FU-treatment [19]. These findings indicate
that some degree of oxidative stress and cellular damage
takes place in animal hearts during 5-FU-treatment. Like-
wise, Kinhult et al. [24] suggested that 5-FU-induced
damage to the arterial endothelium may be due to gen-
eration of free radicals, resulting in lipid peroxidation.
Their demonstration of a protective effect of probucol
on arterial endothelium in rabbits treated with 5-FU
supports this statement. Probucol increases SOD and
GSH-Px activities in animals, thereby improving anti-
oxidant potential [77-79].
The role of iron and other redox active metals in for-
mation of ROS and promotion of myocardial oxidative
stress during 5-FU treatment was investigated in two
studies, with conflicting results [18,19]. Increased iron
levels were demonstrated in the isolated perfused rat
heart by Millart et al. [19], but no changes in iron levels
were found in guinea pigs by Durak et al. [18]. Iron cata-
lyzes the formation of hydroxyl radicals, promoting oxi-
dative stress. If iron and oxidative stress plays a role in
5-FU-induced cardiotoxicity then iron-chelators could
be a possible treatment option. Taken together, the role
of oxidative stress in the pathogenesis of 5-FU cardio-
toxicity is not well-established, and the source of ROS
formation remains undefined. In vitro studies of free
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role of iron-chelators may confirm or disprove this
hypothesis.
The theory of vasospasm
The theory of vasospasm leading to myocardial ischemia
has been proposed, because coronary angiography
largely failed to show stenoses in patients with acute
5-FU-induced cardiotoxicity [47-63]. Moreover, coronary
artery vasospasm has been visualized during coronary
angiography in a few cases [80-82], and peripherally, vaso-
constriction of the brachial artery appears immediately
after 5-FU-injection [27,28]. It is anticipated that vasocon-
striction measured peripherally after 5-FU-injection oc-
curs in the coronary arteries as well. However, invasive
methods such as cardiac catheterization and coronary
angiography during infusion are necessary to prove
vasospasm in the coronary arteries. While vasoconstric-
tion is observed immediately after 5-FU injection, clinical
cardiotoxicity often presents at the end of infusion, or
hours to days later [2]. Moreover, cardiotoxicity may
occur after several series of 5-FU or capecitabine. Hence,
it remains to be elucidated in which circumstances
5-FU-induced vasoconstriction leads to clinical signs
of cardiotoxicity.
In the search for the mechanism that leads to 5-FU-
induced vasoconstriction, Mosseri et al. [26], exposed
rabbit aorta rings to a range of substances that are
involved in regulation of vascular tonus. The authors
found preserved acetylcholine-induced relaxation of
the vascular wall, and that glyceryl nitrate prevented
5-FU-induced vasoconstrictions [26]. Acetylcholine is an
endothelium-dependent vasodilator that induces vaso-
dilation through the NO-cGMP pathway [83]. Intact
endothelial cells are a prerequisite for acetylcholine-
induced vasodilation, and in the absence of endothe-
lial cells acetylcholine leads to vasoconstriction [83]. As
both acetylcholine-induced vascular relaxation and vascu-
lar relaxation by glyceryl nitrate were intact during 5-FU
infusion, it seems unlikely that 5-FU causes functional
vasoconstriction through impaired vasodilatory response.
In contrast, Mosseri et al. [26] showed that PK-C might
be a mediator of 5-FU-induced vasoconstriction. PK-C
requires Ca2+ and phospholipid for its activation [84]. Di-
acylglycerol (DAG) considerably increases the affinity of
PK-C for Ca2+, and thereby fully activates PK-C without
a net increase in the Ca2+ concentration [84]. DAG is
formed from phosphatidylinositol-4,5-bisphosphate (PIP2)
cleavage, but neomycin, a competitive inhibitor of the
phosphodiesterase that cleaves PIP2, did not alter the 5-
FU-induced vasoconstriction [26]. That denotes that PK-C
might not be activated through cleavage of PIP2 and DAG
formation, but rather through an unknown mechanism, or
directly from 5-FU. Furthermore, there was no evidencefor any modulation of 5-FU-induced vasoconstriction by
membrane receptor blockers or activators of the cyclooxy-
genase pathway [26]. Noteworthy is that no effect of the
Ca2+-antagonists, verapamil and diltiazem, which are often
used to treat vasospasm, were seen [26].
The high plasma levels of endothelin-1 observed by
Thyss et al. [35] in 5-FU treated patients, and especially
in patients experiencing 5-FU-induced cardiotoxicity,
may support the hypothesis of 5-FU-induced vasocon-
striction. Endothelin-1 is a potent vasoconstrictor pro-
duced by endothelial cells, cardiomyocytes and cardiac
fibroblasts, but it is also produced in several noncar-
diac tissues such as the lungs [85,86]. Endothelin-1 is
known to have a regulatory role in coronary vascular
resistance and myocardial capillary blood flow in cor-
onary artery diseases [86-88]. Hypoxia, ischemia or
shear stress are stimuli that induce the synthesis and
secretion of endothelin-1 in vascular endothelial cells
[85]. Endothelin-1 is synthesized from the precursor pep-
tide big endothelin [85]. A trend towards increased big
endothelin levels in the plasma of 5-FU treated patients
was found by Salepci et al. [27], but this trend was not
confined to patients who developed vasoconstrictions. As
endothelin-1 and some big endothelin-1 are secreted
mainly towards the adjacent smooth-muscle layer of
blood vessel wall, only smaller amounts of the peptides
reach the lumen of the vessel and contribute to the
plasma levels [85]. Hence, it is possible that the raised
endothelin-1 in plasma may come from cellular sources
other than the endothelial cells. To further elucidate the
role of endothelins in 5-FU-induced cardiotoxicity, the
cellular source of endothelin-1 and the contribution of
endothelin-1 to vasomotor tone during 5-FU infusion
should be studied.
5-FU-induced changes in rheological factors and
cardiotoxicity
Reversible transformation of RBCs into echinocytic
shapes, increased membrane fluidity of RBCs and altered
metabolism in terms of a rapid depletion of pO2, produc-
tion of 2,3-BPG and decreased ATP levels [30-32]
diminish the ability of RBCs to transfer oxygen to the
heart. However, cisplatin induced almost similar changes
in RBC morphology and membrane fluidity [32]. As cis-
platin does not cause myocardial ischemia, which is the
primary manifestation of 5-FU-induced cardiotoxicity,
this finding might indicate that changes in RBC shape
and membrane fluidity are not the principal cause of
5-FU-induced ischemia [32]. In contrast, significant
depletion of pO2, increase in deoxy-hemoglobin levels, in-
crease in 2,3-BPG levels and decrease in ATP levels were
only observed for erythrocytes treated with 5-FU alone
and erythrocytes treated with the combination of 5-FU
and cisplatin. Hence, altered RBC metabolism might be a
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whether the changes in RBC metabolism and morphology
observed in vitro also occur in vivo. Also, the link between
these changes and clinical signs of cardiotoxicity in pa-
tients is not proven. It is unlikely that changes in blood
viscosity are a part of the pathogenesis of 5-FU induced
cardiotoxicity, as studies on blood viscosity reported con-
flicting results [29,33].
Other proposed mechanisms for 5-FU-induced
cardiotoxicity
Few other mechanisms for 5-FU-induced cardiotoxicity
have been proposed. Lemaire et al. [11] proposed that
5-FU cardiotoxicity was due to degradation products
formed in the basic medium in which 5-FU is dissolved.
The compound thought to be responsible for the cardi-
otoxicity is fluoroacetate, which is formed through alka-
line hydrolysis of 5-FU and by catabolism of 5-FU in
the liver [89]. However, the consistent nature of 5-FU
and capecitabine-induced cardiotoxicity, regardless of
the solutions or formulations used, makes it unlikely
that 5-FU cardiotoxicity is due to degradation products
formed in the solution of 5-FU in a basic medium.
Thus, if fluoroacetate plays a role in 5-FU-induced car-
diotoxicity it is likely because of metabolism of 5-FU to
fluoroacetate in the liver.
Toxic myocarditis has been proposed by Sasson et al.
[90], as they found biventricular dilation and diffusely
scattered areas of cell necrosis associated with an inflam-
matory infiltrate, on autopsy of a case of 5-FU-induced
fatal cardiogenic shock.
Limitations
First, the selection of studies concerning the pathophysi-
ology of 5-FU cardiotoxicity could not be based on
objective criteria, but instead relied on the author’s judg-
ments of which studies were concerned with the patho-
physiology of 5-FU-induced cardiotoxicity. Still, we made
a broad inclusion of studies that investigated the effects
of 5-FU on any part of the cardiovascular system. There-
fore, we believe that this review makes up a comprehen-
sive and systematic synthesis of the results from the
pathophysiological studies of 5-FU cardiotoxicity. How-
ever, as our literature search was restricted to English, a
few studies may have been missed.
Second, most experimental studies included few ani-
mals and were only carried out once. Hence the statis-
tical powers in these studies were low and the findings
rarely confirmed in other studies, which makes those
findings less consistent.
Third, extrapolation of results from in vitro and ex vivo
studies to in vivo settings should be done with precau-
tion, as isolated cells in vitro and isolated organs may not
behave the same as in in vivo settings. There are alsoimportant differences between species, and more import-
antly, between animals and humans.
Fourth, some in vivo animal experiments used re-
peated administrations of 5-FU, but numerous studies
have used regimens in which animals were treated with
only a single and/or a very high 5-FU dose. In clinical
practice, 5-FU is often administered according to the De
Gramont schedule where a short bolus infusion is given
followed by a 48-hour continuous infusion. Hence, dif-
ferences in administration schedules and doses may also
limit the extrapolation of the results from these studies
to clinical settings.
Fifth, most of the findings in the human studies were
not confined to patients experiencing cardiotoxicity, as
only NT-proBNP and endothelin-1 were higher in pa-
tients with cardiotoxicity. Hence, for nearly all findings,
their role in the pathogenesis of cardiotoxicity is still
unclear.
Finally, some types of studies that can be conducted in
animals are difficult to carry out in human patients. For
example, biopsy samples are hard to obtain and carry a
risk of bleeding and myocardial wall perforation for the
patient. Such risks may outweigh the expected benefit
for the patient, and therefore make such procedures un-
reasonable to perform.
Conclusions
This review indicates that there is no evidence for a single
mechanism responsible for 5-FU-induced cardiotoxicity,
and the underlying mechanisms might be multifactorial.
The proposed cardiotoxic pathways leading to myocardial
and endothelial damage are not mutually exclusive, and
they may each contribute to cardiovascular dysfunction
resulting in the clinical picture of cardiotoxicity. Further
research is needed to elucidate the pathogenesis of this
side effect. Studies on cardiac and endothelial cell lines
might contribute to further elucidation of the cellular re-
sponse to 5-FU. A human study with continuous ECG
monitoring concurrent with measurements of the brachial
artery diameters could be interesting, to explore the theory
of arterial vasospasm leading to myocardial ischemia.
Other methods to further study the pathogenesis of 5-FU-
induced cardiotoxicity could be studies of myocardial
perfusion with magnetic resonance scanning or PET rubid-
ium scanning of the heart in patients presenting with signs
of cardiotoxicity.Additional files
Additional file 1: PRISMA Checklist. The PRISMA Checklist for this
systematic review.
Additional file 2: Characteristics and results of the included
studies. This table shows the characteristics of the studies included
in the review.
Polk et al. BMC Pharmacology and Toxicology 2014, 15:47 Page 9 of 11
http://www.biomedcentral.com/2050-6511/15/47Competing interests
The authors declare that they have no competing interests.Authors’ contributions
AP participated in the design of the review, the literature search, the study
selection process and the data synthesis, and drafted the manuscript. KV and
MVN participated in the design of the review. DN participated in the design
of the review, the literature search, the study selection process and helped
with the data synthesis. All authors read and approved the final version of
the manuscript.
Received: 5 March 2014 Accepted: 19 August 2014
Published: 4 September 2014References
1. Malet-Martino M, Jolimaitre P, Martino R: The prodrugs of 5-fluorouracil.
Curr Med Chem Anticancer Agents 2002, 2:267–310.
2. Polk A, Vaage-Nilsen M, Vistisen K, Nielsen DL: Cardiotoxicity in cancer
patients treated with 5-fluorouracil or capecitabine: A systematic review
of incidence, manifestations and predisposing factors. Cancer Treat Rev
2013, 39:974–84.
3. Kosmas C, Kallistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonakis N,
Karabelis A, Tsavaris N: Cardiotoxicity of fluoropyrimidines in different
schedules of administration: a prospective study. J Cancer Res Clin Oncol
2008, 134:75–82.
4. Meydan N, Kundak I, Yavuzsen T, Oztop I, Barutca S, Yilmaz U, Alakavuklar MN:
Cardiotoxicity of de Gramont’s regimen: incidence, clinical characteristics
and long-term follow-up. Jpn J Clin Oncol 2005, 35:265–270.
5. Meyer CC, Calis KA, Burke LB, Walawander CA, Grasela TH: Symptomatic
cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy 1997,
17:729–736.
6. Ng M, Cunningham D, Norman AR: The frequency and pattern of
cardiotoxicity observed with capecitabine used in conjunction with
oxaliplatin in patients treated for advanced colorectal cancer (CRC).
Eur J Cancer 2005, 41:1542–1546.
7. Rezkalla S, Kloner RA, Ensley J, al-Sarraf M, Revels S, Olivenstein A, Bhasin S,
Kerpel-Fronious S, Turi ZG: Continuous ambulatory ECG monitoring during
fluorouracil therapy: a prospective study. J Clin Oncol 1989, 7:509–514.
8. Jensen SA, Sorensen JB: 5-fluorouracil-based therapy induces
endovascular injury having potential significance to development of
clinically overt cardiotoxicity. Cancer Chemother Pharmacol 2012, 69:57–64.
9. Kinhult S, Albertsson M, Eskilsson J, Cwikiel M: Antithrombotic treatment in
protection against thrombogenic effects of 5-fluorouracil on vascular
endothelium: a scanning microscopy evaluation. Scanning 2001, 23:1–8.
10. Kuzel T, Esparaz B, Green D, Kies M: Thrombogenicity of intravenous
5-fluorouracil alone or in combination with cisplatin. Cancer 1990,
65:885–889.
11. Lemaire L, Malet-Martino MC, De ᅟ FM, Martino R, Lasserre B: Cardiotoxicity
of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of
this drug. Br J Cancer 1992, 66:119–127.
12. Matsubara I, Kamiya J, Imai S: Cardiotoxic effects of 5-fluorouracil in the
guinea pig. Jpn J Pharmacol 1980, 30:871–879.
13. Tsavaris N, Kosmas C, Vadiaka M, Efremidis M, Zinelis A, Beldecos D,
Sakelariou D, Koufos C, Stamatelos G: Cardiotoxicity following different
doses and schedules of 5-fluorouracil administration for malignancy – a
survey of 427 patients. Med Sci Monit 2002, 8:I51–I57.
14. Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement. PLoS Med
2009, 6:e1000097.
15. Kumar S, Gupta RK, Samal N: 5-fluorouracil induced cardiotoxicity in
albino rats. Mater Med Pol 1995, 27:63–66.
16. Tsibiribi P, Bui-Xuan C, Bui-Xuan B, Lombard-Bohas C, Duperret S, Belkhiria M,
Tabib A, Maujean G, Descotes J, Timour Q: Cardiac lesions induced
by 5-fluorouracil in the rabbit. Hum Exp Toxicol 2006, 25:305–309.
17. Lamberti M, Porto S, Marra M, Zappavigna S, Grimaldi A, Feola D, Pesce D,
Naviglio S, Spina A, Sannolo N, Caraglia M: 5-Fluorouracil induces
apoptosis in rat cardiocytes through intracellular oxidative stress.
J Exp Clin Cancer Res 2012, 31:60.
18. Durak I, Karaayvaz M, Kavutcu M, Cimen MY, Kacmaz M, Buyukkocak S,
Ozturk HS: Reduced antioxidant defense capacity in myocardial tissuefrom guinea pigs treated with 5-fluorouracil. J Toxicol Environ Health A
2000, 59:585–589.
19. Millart H, Kantelip JP, Platonoff N, Descous I, Trenque T, Lamiable D, Choisy H:
Increased iron content in rat myocardium after 5-fluorouracil chronic
administration. Anticancer Res 1993, 13:779–783.
20. Millart H, Brabant L, Lorenzato M, Lamiable D, Albert O, Choisy H: The
effects of 5-fluorouracil on contractility and oxygen uptake of the
isolated perfused rat heart. Anticancer Res 1992, 12:571–576.
21. Satoh H, Hashimoto K: Effects of ftorafur and 5-fluorouracil on the canine
sinoatrial node. Jpn J Pharmacol 1983, 33:357–362.
22. Cwikiel M, Zhang B, Eskilsson J, Wieslander JB, Albertsson M: The influence
of 5-fluorouracil on the endothelium in small arteries. An electron
microscopic study in rabbits. Scanning Microsc 1995, 9:561–576.
23. Cwikiel M, Eskilsson J, Wieslander JB, Stjernquist U, Albertsson M: The
appearance of endothelium in small arteries after treatment with
5-fluorouracil. An electron microscopic study of late effects in rabbits.
Scanning Microsc 1996, 10:805–818.
24. Kinhult S, Albertsson M, Eskilsson J, Cwikiel M: Effects of probucol on
endothelial damage by 5-fluorouracil. Acta Oncol 2003, 42:304–308.
25. Cwikiel M, Eskilsson J, Albertsson M, Stavenow L: The influence of
5-fluorouracil and methotrexate on vascular endothelium. An
experimental study using endothelial cells in the culture. Ann Oncol
1996, 7:731–737.
26. Mosseri M, Fingert HJ, Varticovski L, Chokshi S, Isner JM: In vitro evidence
that myocardial ischemia resulting from 5-fluorouracil chemotherapy is
due to protein kinase C-mediated vasoconstriction of vascular smooth
muscle. Cancer Res 1993, 53:3028–3033.
27. Salepci T, Seker M, Uyarel H, Gumus M, Bilici A, Ustaalioglu BB, Ozturk A,
Sonmez B, Orcun A, Ozates M, Irmak R, Yaylaci M: 5-Fluorouracil induces
arterial vasoconstrictions but does not increase angiotensin II levels.
Med Oncol 2010, 27:416–420.
28. Sudhoff T, Enderle MD, Pahlke M, Petz C, Teschendorf C, Graeven U,
Schmiegel W: 5-Fluorouracil induces arterial vasocontractions. Ann Oncol
2004, 15:661–664.
29. Baerlocher GM, Beer JH, Owen GR, Meiselman HJ, Reinhart WH: The anti-
neoplastic drug 5-fluorouracil produces echinocytosis and affects blood
rheology. Br J Haematol 1997, 99:426–432.
30. Spasojevic I, Maksimovic V, Zakrzewska J, Bacic G: Effects of 5-fluorouracil
on erythrocytes in relation to its cardiotoxicity: membrane structure and
functioning. J Chem Inf Model 2005, 45:1680–1685.
31. Spasojevic I, Zakrzewska J, Bacic GG: 31P NMR spectroscopy and
polarographic combined study of erythrocytes treated with 5-fluorouracil:
cardiotoxicity-related changes in ATP, 2,3-BPG, and O2 metabolism. Ann N Y
Acad Sci 2005, 1048:311–320.
32. Spasojevic I, Jelic S, Zakrzewska J, Bacic G: Decreased oxygen transfer
capacity of erythrocytes as a cause of 5-fluorouracil related ischemia.
Molecules 2009, 14:53–67.
33. Cwikiel M, Persson SU, Larsson H, Albertsson M, Eskilsson J: Changes of
blood viscosity in patients treated with 5-fluorouracil–a link to cardiotoxicity?
Acta Oncol 1995, 34:83–85.
34. Jensen SA, Hasbak P, Mortensen J, Sorensen JB: Fluorouracil induces
myocardial ischemia with increases of plasma brain natriuretic peptide
and lactic acid but without dysfunction of left ventricle. J Clin Oncol 2010,
28:5280–5286.
35. Thyss A, Gaspard MH, Marsault R, Milano G, Frelin C, Schneider M: Very high
endothelin plasma levels in patients with 5-FU cardiotoxicity. Ann Oncol
1992, 3:88.
36. Wenzel DG, Cosma GN: A model system for measuring comparative
toxicities of cardiotoxic drugs for cultured rat heart myocytes, endothelial
cells and fibroblasts. II. Doxorubicin, 5-fluorouracil and cyclophosphamide.
Toxicology 1984, 33:117–128.
37. Tamatsu H, Nakazawa M, Imai S, Watari H: 31P-topical nuclear magnetic
resonance (31P-TMR) studies of cardiotoxic effects of 5-fluorouracil
(5-FU) and 5′-deoxy-5-fluorouridine (5′-DFUR). Jpn J Pharmacol 1984,
34:375–379.
38. Barnabe N, Zastre JA, Venkataram S, Hasinoff BB: Deferiprone protects
against doxorubicin-induced myocyte cytotoxicity. Free Radic Biol Med
2002, 33:266–275.
39. Hasinoff BB, Patel D, Wu X: The oral iron chelator ICL670A (deferasirox)
does not protect myocytes against doxorubicin. Free Radic Biol Med 2003,
35:1469–1479.
Polk et al. BMC Pharmacology and Toxicology 2014, 15:47 Page 10 of 11
http://www.biomedcentral.com/2050-6511/15/4740. Hershko C, Link G, Tzahor M, Pinson A: The role of iron and iron chelators
in anthracycline cardiotoxicity. Leuk Lymphoma 1993, 11:207–214.
41. Kang YJ, Zhou ZX, Wang GW, Buridi A, Klein JB: Suppression by
metallothionein of doxorubicin-induced cardiomyocyte apoptosis
through inhibition of p38 mitogen-activated protein kinases. J Biol Chem
2000, 275:13690–13698.
42. Kim DS, Kim HR, Woo ER, Hong ST, Chae HJ, Chae SW: Inhibitory effects of
rosmarinic acid on adriamycin-induced apoptosis in H9c2 cardiac muscle
cells by inhibiting reactive oxygen species and the activations of c-Jun
N-terminal kinase and extracellular signal-regulated kinase. Biochem
Pharmacol 2005, 70:1066–1078.
43. Kwok JC, Richardson DR: Unexpected anthracycline-mediated alterations
in iron-regulatory protein-RNA-binding activity: the iron and copper
complexes of anthracyclines decrease RNA-binding activity. Mol
Pharmacol 2002, 62:888–900.
44. Minotti G, Ronchi R, Salvatorelli E, Menna P, Cairo G: Doxorubicin
irreversibly inactivates iron regulatory proteins 1 and 2 in
cardiomyocytes: evidence for distinct metabolic pathways and
implications for iron-mediated cardiotoxicity of antitumor therapy.
Cancer Res 2001, 61:8422–8428.
45. L’Ecuyer T, Horenstein MS, Thomas R, Vander HR: Anthracycline-induced
cardiac injury using a cardiac cell line: potential for gene therapy
studies. Mol Genet Metab 2001, 74:370–379.
46. Sawyer DB, Fukazawa R, Arstall MA, Kelly RA: Daunorubicin-induced
apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ Res
1999, 84:257–265.
47. Ozturk MA, Ozveren O, Cinar V, Erdik B, Oyan B: Takotsubo syndrome: an
underdiagnosed complication of 5-fluorouracil mimicking acute
myocardial infarction. Blood Coagul Fibrinolysis 2013, 24:90–94.
48. Kim SM, Kwak CH, Lee B, Kim SB, Sir JJ, Cho WH, Choi SK: A case of severe
coronary spasm associated with 5-fluorouracil chemotherapy. Korean J
Intern Med 2012, 27:342–345.
49. Tsiamis E, Synetos A, Stefanadis C: Capecitabine may induce coronary
artery vasospasm. Hellenic J Cardiol 2012, 53:320–323.
50. Shah NR, Shah A, Rather A: Ventricular fibrillation as a likely consequence
of capecitabine-induced coronary vasospasm. J Oncol Pharm Pract 2012,
18:132–135.
51. Basselin C, Fontanges T, Descotes J, Chevalier P, Bui-Xuan B, Feinard G,
Timour Q: 5-Fluorouracil-induced Tako-Tsubo-like syndrome. Pharmacotherapy
2011, 31:226.
52. Calik AN, Celiker E, Velibey Y, Cagdas M, Guzelburc O: Initial dose effect of
5-fluorouracil: rapidly improving severe, acute toxic myopericarditis.
Am J Emerg Med 2012, 30:257–3.
53. Atar A, Korkmaz ME, Ozin B: Two cases of coronary vasospasm induced by
5-fluorouracil. Anadolu Kardiyol Derg 2010, 10:461–462.
54. Tajik R, Saadat H, Taherkhani M, Movahed MR: Angina induced by
5-fluorouracil infusion in a patient with normal coronaries. Am Heart
Hosp J 2010, 8:E111–E112.
55. Camaro C, Danse PW, Bosker HA: Acute chest pain in a patient treated
with capecitabine. Neth Heart J 2009, 17:288–291.
56. Gianni M, Dentali F, Lonn E: 5 flourouracil-induced apical ballooning
syndrome: a case report. Blood Coagul Fibrinolysis 2009, 20:306–308.
57. Yung LT, McCrea WA: Capecitabine induced acute coronary syndrome.
BMJ Case Rep 2009, 2009.
58. Scott PA, Ferchow L, Hobson A, Curzen NP: Coronary spasm induced by
capecitabine mimicks ST elevation myocardial infarction. Emerg Med J
2008, 25:699–700.
59. Canale ML, Camerini A, Stroppa S, Porta RP, Caravelli P, Mariani M, Balbarini A,
Ricci S: A case of acute myocardial infarction during 5-fluorouracil infusion.
J Cardiovasc Med (Hagerstown) 2006, 7:835–837.
60. Cardinale D, Colombo A, Colombo N: Acute coronary syndrome induced
by oral capecitabine. Can J Cardiol 2006, 22:251–253.
61. Mafrici A, Alberti A, Corrada E, Ferrari S, Marenna B: Management of
patients with persistent chest pain and ST-segment elevation during
5-fluorouracil treatment: report about two cases. Ital Heart J 2003,
4:895–899.
62. McGlinchey PG, Webb ST, Campbell NP: 5-fluorouracil-induced
cardiotoxicity mimicking myocardial infarction: a case report. BMC
Cardiovasc Disord 2001, 1:3.
63. Schnetzler B, Popova N, Collao LC, Sappino AP: Coronary spasm induced
by capecitabine. Ann Oncol 2001, 12:723–724.64. Prandoni P, Falanga A, Piccioli A: Cancer and venous thromboembolism.
Lancet Oncol 2005, 6:401–410.
65. Okholm M, Iversen LH, Thorlacius-Ussing O, Ejlersen E, Boesby S: Fibrin and
fibrinogen degradation products in plasma of patients with colorectal
adenocarcinoma. Dis Colon Rectum 1996, 39:1102–1106.
66. Oya M, Akiyama Y, Okuyama T, Ishikawa H: High preoperative plasma
D-dimer level is associated with advanced tumor stage and short
survival after curative resection in patients with colorectal cancer.
Jpn J Clin Oncol 2001, 31:388–394.
67. Blackwell K, Hurwitz H, Lieberman G, Novotny W, Snyder S, Dewhirst M,
Greenberg C: Circulating D-dimer levels are better predictors of overall
survival and disease progression than carcinoembryonic antigen levels
in patients with metastatic colorectal carcinoma. Cancer 2004, 101:77–82.
68. Iversen LH, Okholm M, Thorlacius-Ussing O: Pre- and postoperative state
of coagulation and fibrinolysis in plasma of patients with benign and
malignant colorectal disease–a preliminary study. Thromb Haemost 1996,
76:523–528.
69. Damin DC, Rosito MA, Gus P, Roisemberg I, Bandinelli E, Schwartsmann G:
Von Willebrand factor in colorectal cancer. Int J Colorectal Dis 2002,
17:42–45.
70. Rohsig LM, Damin DC, Stefani SD, Castro CG Jr, Roisenberg I, Schwartsmann G:
von Willebrand factor antigen levels in plasma of patients with malignant
breast disease. Braz J Med Biol Res 2001, 34:1125–1129.
71. Gil-Bazo I, Catalan G,V, Alonso GA, Rodriguez RJ, Paramo Fernandez JA,
de la Camara GJ, Hernandez Lizoain JL, Garcia-Foncillas LJ: Impact of
surgery and chemotherapy on von Willebrand factor and vascular
endothelial growth factor levels in colorectal cancer. Clin Transl
Oncol 2005, 7:150–155.
72. Wang WS, Lin JK, Lin TC, Chiou TJ, Liu JH, Yen CC, Chen PM: Plasma von
Willebrand factor level as a prognostic indicator of patients with
metastatic colorectal carcinoma. World J Gastroenterol 2005, 11:2166–2170.
73. Suzuki T, Nakanishi H, Hayashi A: Cardiac toxicity of 5-fluorouracil in rabbits.
Jpn J Pharmacol 1977, 27 s:137. Ref Type: Abstract.
74. Sterba M, Popelova O, Vavrova A, Jirkovsky E, Kovarikova P, Gersl V, Simunek T:
Oxidative stress, redox signaling, and metal chelation in anthracycline
cardiotoxicity and pharmacological cardioprotection. Antioxid Redox Signal
2013, 18:899–929.
75. Kehrer JP: The Haber-Weiss reaction and mechanisms of toxicity.
Toxicology 2000, 149:43–50.
76. Nielsen F, Mikkelsen BB, Nielsen JB, Andersen HR, Grandjean P: Plasma
malondialdehyde as biomarker for oxidative stress: reference interval
and effects of life-style factors. Clin Chem 1997, 43:1209–1214.
77. Li T, Danelisen I, Bello-Klein A, Singal PK: Effects of probucol on changes of
antioxidant enzymes in adriamycin-induced cardiomyopathy in rats.
Cardiovasc Res 2000, 46:523–530.
78. Siveski-Iliskovic N, Kaul N, Singal PK: Probucol promotes endogenous
antioxidants and provides protection against adriamycin-induced
cardiomyopathy in rats. Circulation 1994, 89:2829–2835.
79. Kaul N, Siveski-Iliskovic N, Thomas TP, Hill M, Khaper N, Singal PK: Probucol
improves antioxidant activity and modulates development of diabetic
cardiomyopathy. Nutrition 1995, 11:551–554.
80. Alter P, Herzum M, Soufi M, Schaefer JR, Maisch B: Cardiotoxicity of
5-fluorouracil. Cardiovasc Hematol Agents Med Chem 2006, 4:1–5.
81. Shoemaker LK, Arora U, Rocha Lima CM: 5-fluorouracil-induced coronary
vasospasm. Cancer Control 2004, 11:46–49.
82. Luwaert RJ, Descamps O, Majois F, Chaudron JM, Beauduin M: Coronary
artery spasm induced by 5-fluorouracil. Eur Heart J 1991, 12:468–470.
83. Schwartz BG, Economides C, Mayeda GS, Burstein S, Kloner RA: The
endothelial cell in health and disease: its function, dysfunction,
measurement and therapy. Int J Impot Res 2010, 22:77–90.
84. Nishizuka Y: Studies and perspectives of protein kinase C. Science 1986,
233:305–312.
85. Levin ER: Endothelins. N Engl J Med 1995, 333:356–363.
86. Khimji AK, Rockey DC: Endothelin–biology and disease. Cell Signal 2010,
22:1615–1625.
87. MacCarthy PA, Pegge NC, Prendergast BD, Shah AM, Groves PH: The
physiological role of endogenous endothelin in the regulation of human
coronary vasomotor tone. J Am Coll Cardiol 2001, 37:137–143.
88. Kinlay S, Behrendt D, Wainstein M, Beltrame J, Fang JC, Creager MA,
Selwyn AP, Ganz P: Role of endothelin-1 in the active constriction of
human atherosclerotic coronary arteries. Circulation 2001, 104:1114–1118.
Polk et al. BMC Pharmacology and Toxicology 2014, 15:47 Page 11 of 11
http://www.biomedcentral.com/2050-6511/15/4789. Arellano M, Malet-Martino M, Martino R, Gires P: The anti-cancer drug
5-fluorouracil is metabolized by the isolated perfused rat liver and in rats
into highly toxic fluoroacetate. Br J Cancer 1998, 77:79–86.
90. Sasson Z, Morgan CD, Wang B, Thomas G, MacKenzie B, Platts ME:
5-Fluorouracil related toxic myocarditis: case reports and pathological
confirmation. Can J Cardiol 1994, 10:861–864.
doi:10.1186/2050-6511-15-47
Cite this article as: Polk et al.: A systematic review of the pathophysiology
of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacology and Toxicology
2014 15:47.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
